WO1998058965A3 - B7-binding molecules for treating immune diseases - Google Patents

B7-binding molecules for treating immune diseases Download PDF

Info

Publication number
WO1998058965A3
WO1998058965A3 PCT/EP1998/003791 EP9803791W WO9858965A3 WO 1998058965 A3 WO1998058965 A3 WO 1998058965A3 EP 9803791 W EP9803791 W EP 9803791W WO 9858965 A3 WO9858965 A3 WO 9858965A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
antigen
binding molecules
immune diseases
cross
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/003791
Other languages
French (fr)
Other versions
WO1998058965A2 (en
Inventor
Katrien Lorre
Erwin Sablon
Marie-Ange Buyse
Alfons Bosman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Priority to AU88005/98A priority Critical patent/AU8800598A/en
Priority to EP98939523A priority patent/EP0988321A2/en
Priority to CA002292415A priority patent/CA2292415A1/en
Publication of WO1998058965A2 publication Critical patent/WO1998058965A2/en
Publication of WO1998058965A3 publication Critical patent/WO1998058965A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to molecules, such as diabodies, tri- and tetravalent antibodies and small antigen binding peptides, which can cross-link or cross-react with the costimulatory molecules B7.1 and B7.2 expressed on professional antigen presenting cells (APCs) leading to the inhibition of antigen-specific T cell activation. The present invention also concerns methods to produce these molecules and use of these molecules to treat diseases, such as transplant rejection, graft versus host disease (GVHD), allergy and autoimmune diseases, where antigen-specific T cell activation is pathogenic.
PCT/EP1998/003791 1997-06-20 1998-06-22 B7-binding molecules for treating immune diseases Ceased WO1998058965A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU88005/98A AU8800598A (en) 1997-06-20 1998-06-22 B7-binding molecules for treating immune diseases
EP98939523A EP0988321A2 (en) 1997-06-20 1998-06-22 B7-binding molecules for treating immune diseases
CA002292415A CA2292415A1 (en) 1997-06-20 1998-06-22 B7-binding molecules for treating immune diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97870092.0 1997-06-20
EP97870092 1997-06-20

Publications (2)

Publication Number Publication Date
WO1998058965A2 WO1998058965A2 (en) 1998-12-30
WO1998058965A3 true WO1998058965A3 (en) 1999-05-14

Family

ID=8231013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/003791 Ceased WO1998058965A2 (en) 1997-06-20 1998-06-22 B7-binding molecules for treating immune diseases

Country Status (4)

Country Link
EP (1) EP0988321A2 (en)
AU (1) AU8800598A (en)
CA (1) CA2292415A1 (en)
WO (1) WO1998058965A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068133A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
WO2001068134A2 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Therapies that improve graft survival, using antibodies against a b7 antigen
WO2001068132A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of a combination of agents that modulate b7 activity in inhibiting intestinal allograft rejection
CN101289511A (en) 2000-04-11 2008-10-22 杰南技术公司 Multivalent antibodies and uses therefore
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
CA2412377A1 (en) 2000-06-06 2001-12-13 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
WO2003014293A2 (en) * 2001-08-02 2003-02-20 Eli Lilly And Company Novel polypeptide analogs and fusions and their methods of use
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EA012622B1 (en) 2004-06-01 2009-10-30 Домэнтис Лимитед Bispecific fusion antibodies with enhanced serum half-life
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
KR20070084069A (en) 2004-10-08 2007-08-24 도만티스 리미티드 Single domain antibody against TENF1 and method of using the same
CA2589800A1 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
AR072571A1 (en) 2008-07-18 2010-09-08 Bristol Myers Squibb Co MONOVALENT COMPOSITIONS FOR UNION TO CD28 AND USE PROCEDURES
NZ592420A (en) 2008-10-02 2012-12-21 Emergent Product Dev Seattle Cd86 antagonist multi-target binding proteins
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
EP3270943A4 (en) * 2015-03-16 2018-10-17 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Isolated peptides derived from the b7 ligand dimer interface and uses thereof
AU2016350701B2 (en) 2015-11-02 2021-08-19 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
US20190225701A1 (en) 2016-09-26 2019-07-25 The Brigham And Women's Hospital, Inc. Regulators of b cell-mediated immunosuppression
WO2018201014A1 (en) 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
CN110305221B (en) * 2018-03-27 2022-10-11 孙嘉琳 Enhanced anti-tumor fusion protein, preparation method and application
CN110305220B (en) * 2018-03-27 2022-10-11 孙嘉琳 Cancer-targeted enhanced anti-tumor fusion protein and preparation method and application thereof
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
CA3227592A1 (en) * 2021-09-22 2023-03-30 Gregory KAPP Methods and systems for determining polypeptide interactions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022619A1 (en) * 1994-02-18 1995-08-24 Chiron Corporation B7-1-specific ligands, and their use for the induction of t cell anergy
WO1996014865A1 (en) * 1994-11-10 1996-05-23 Repligen Corporation Methods for inhibiting graft versus host disease in bone marrow transplantation
WO1996040878A1 (en) * 1995-06-07 1996-12-19 Idec Pharmaceuticals Corporation Monkey monoclonal antibodies specific to human b7.1 and/or b7.2 primatized forms, pharmaceutical compositions
WO1998003670A1 (en) * 1996-07-23 1998-01-29 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022619A1 (en) * 1994-02-18 1995-08-24 Chiron Corporation B7-1-specific ligands, and their use for the induction of t cell anergy
WO1996014865A1 (en) * 1994-11-10 1996-05-23 Repligen Corporation Methods for inhibiting graft versus host disease in bone marrow transplantation
WO1996040878A1 (en) * 1995-06-07 1996-12-19 Idec Pharmaceuticals Corporation Monkey monoclonal antibodies specific to human b7.1 and/or b7.2 primatized forms, pharmaceutical compositions
WO1998003670A1 (en) * 1996-07-23 1998-01-29 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
P. ILIADES ET AL.: "Triabodies: single chain Fv fragments without a linker form trivalent trimers.", FEBS LETTERS, vol. 409, no. 3, 16 June 1997 (1997-06-16), AMSTERDAM, NL, pages 437 - 441, XP002047810 *
P. PERRIN ET AL.: "Distinct requirements of lymph node T cells for B7-1 (CD80) and B7-2 (CD86) costimulation in response to concanavalin A.", THE FASEB JOURNAL, vol. 10, no. 6, 30 April 1996 (1996-04-30), BETHESDA, MD, USA, pages A1454, XP002047809 *
P. PERRIN ET AL.: "Mitogenic stimulation of T cells reveals differing contributions for B7-1 (CD80) and B7-2 (CD86) costimulation.", IMMUNOLOGY, vol. 90, no. 4, April 1997 (1997-04-01), OXFORD, GB, pages 534 - 542, XP002047808 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes

Also Published As

Publication number Publication date
EP0988321A2 (en) 2000-03-29
CA2292415A1 (en) 1998-12-30
WO1998058965A2 (en) 1998-12-30
AU8800598A (en) 1999-01-04

Similar Documents

Publication Publication Date Title
WO1998058965A3 (en) B7-binding molecules for treating immune diseases
DK0752869T3 (en) Cells with numerous altered epitopes on a surface antigen for use in transplantation
NO986173L (en) Procedure for activating dendritic cells
FR12C0004I2 (en) ANTIBODIES TO HUMAN CTLA-4 ANTIGEN AND USE
WO2000023053A3 (en) Artificial antigen-specific cells and related methods
CA2290485A1 (en) Method for the production of non-immunogenic proteins
ATE244891T1 (en) METHOD FOR SELECTION AND PRODUCTION OF T-CELL PEPTIDES EPITOPES AND VACCINES WITH THESE EPITOPES
WO1998021334A3 (en) Antibody mg1 recognizing a small subset of human hematopoietic cells
ATE301471T1 (en) USE OF ANTIBODIES AGAINST CD45RO LEUKOCYTE ANTIGEN FOR IMMUNE MODULATION
CA2295604A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
GB2261666A (en) Multivalent anti-cytokine immunoglobulins
HUP9901688A2 (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
CA2185112A1 (en) Humanized monoclonal antibodies against human interleukin-4
DK0687300T3 (en) LO-CD2a antibody and its uses for inhibiting T cell activation and proliferation
NZ331398A (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof
WO2001079496A3 (en) Ligand for herpes simplex virus entry mediator and methods of use
DE69839943D1 (en) PREVENT IMMUNOACTIVITY THROUGH INHIBITION OR INHIBITION OF ANTIGEN-PRESENTING CELLS
NO972522L (en) Monoclonal antibodies with immunosuppressive activity
Orban et al. A factor shed by lymphoblastoid cell lines of HLA-B27 positive patients with ankylosing spondylitis, specifically modifies the cells of HLA-B27 positive normal individuals
AU6953296A (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
ATE209041T1 (en) TUMOR REJECTION ANTIGENS PRESENTED BY HLA-B44 MOLECULES AND THEIR USE
Gurka et al. 107 Allergen specific T cell clones can be utilized to map allergenic epitopes for T cell activation
WO1996002272A3 (en) Treatment of autoimmune diseases
Adyel et al. Deposition of IgG anti-actin antibodies on kidneys of glomerular nephropathy patients with an enhanced glomerular alpha smooth muscle actin expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2292415

Country of ref document: CA

Ref country code: CA

Ref document number: 2292415

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09468029

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1998939523

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999503793

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1998939523

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998939523

Country of ref document: EP